hsCRP and ET-1 expressions in patients with no-reflow phenomenon after percutaneous coronary intervention

Pakistan Journal of Medical Sciences

Volumn 33, Issue 4, 2017, Pages 920-925

  Liu, Min ^a,b,c   Liang, Tian ^a,b,c   Zhang, Peiying ^a   Zhang, Qing ^c   Lu, Lei ^c   Wang, Zhongliang ^c  

^a XUZHOU CENTRAL HOSPITAL   (China)

^b TCM Hospital of Xuzhou City   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Coronary artery disease; ET 1; Hs CRP; Percutaneous coronary intervention

Indexed keywords

EID: 85028318002     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.334.13059     Document Type: Article

References (24)

1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020-2035. doi: 10.1161/CIR.0b013e31826e1058.
2. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57:e215-367. doi: 10.1016/j.jacc.2011.02.011.
3. Abdel MI, Dantani N, Ihara C, Aimone-Gastin I, Angioï M, Lozniewski A, et al. C-reactive protein and coronary artery disease: addition alevidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J. 1999;137:346-351.
4. Townend JN, Ludman PF, Doshi SN, Khan H, Calvert PA. Assessing flow limitation in patients with stable coronary artery disease. BMJ. 2016;355:i5534.doi: 10.1136/bmj.i5534.
5. Lim SY. No-Reflow Phenomenon by Intracoronary Thrombus in Acute Myocardial Infarction. Chonnam Med J. 2016;52:38-44. doi: 10.4068/cmj.2016.52.1.38.
6. Haugen G, Stray-Pedersen S. Effects of endothelin-1 on vascular tension in human umbilical vessels. Early Hum Dev. 1991;27:25-32.
7. Fernandez AB, Soufer R, Collins D, Soufer A, Ranjbaran H, Burg MM. Tendency to angry rumination predicts stress-provoked endothelin-1 increase in patients with coronary artery disease. Psychosom Med. 2010;72:348-353. doi: 10.1097/PSY.0b013e3181d71982.
8. Tomić M, Galesić K, Markota I. Endothelin-1 and nitric oxide in patients on chronic hemodialysis. Ren Fail. 2008;30:836-842. doi: 10.1080/08860220802356218.
9. Doumatey AP, Zhou J, Adeyemo A, Rotimi C. High sensitivity C-reactive protein (Hs-CRP) remains highly stable in long-term archived human serum. Clin Biochem. 2014;47:315-318. doi: 10.1016/j.clinbiochem.2013.12.014.
10. Soylu K, Yuksel S, Gulel O, Erbay AR, Meric M, Zengin H, et al. The relationship of coronary flow to neutrophil/ lymphocyte ratio in patients undergoing primary percutaneous coronary intervention. J Thorac Dis. 2013;5:258-264. doi: 10.3978/j.issn.2072-1439.2013.05.13.
11. Kim YD, Fomsgaard JS, Heim KF, Ramwell PW, Thomas G, Kagan E, et al. Brief ischemia-reperfusion induces stunning of endothelium in canine coronary artery. Circulation. 1992;85:1473-1482.
12. Cenko E, Ricci B, Kedev S, Kalpak O, Câlmâc L, Vasiljevic Z, et al. The no-reflow phenomenon in the young and in the elderly. Int J Cardiol. 2016;222:1122-1128. doi: 10.1016/j. ijcard.2016.07.209.
13. Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol. 2007;99:442-445. doi: 10.1016/j.amjcard.2006.08.054.
14. Iwakura K. Modulation of individual susceptibility to the no-reflow phenomenon after acute myocardial infarction. Curr Pharm Des. 2013;19:4519-4528.
15. Song R, Chou YI, Kong J, Li J, Pan B, Cui M, et al. Association of endothelial microparticle with NO, eNOS, ET-1, and fractional flow reserve in patients with coronary intermediate lesions. Biomarkers. 2015;20:429-435. doi: 10.3109/1354750X.2015.1094140.
16. Rodríguez-Pascual F, Busnadiego O, Lagares D, Lamas S. Role of endothelin in the cardiovascular system. Pharmacol Res. 2011;63:463-472. doi: 10.1016/j.phrs.2011.01.014.
17. Spinella MJ, Malik AB, Everitt J, Andersen TT. Design and synthesis of a specific endothelin 1 antagonist: effects on pulmonary vasoconstriction. Proc Natl Acad Sci USA. 1991;88:7443-7446.
18. Böhm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007;76(1):8-18. doi: 10.1016/j.cardiores.2007.06.004.
19. Skovsted GF, Kilic S, Edvinsson L. Endothelin-1 and Endothelin-3 Regulate Endothelin Receptor Expression in Rat Coronary Arteries. Basic Clin Pharmacol Toxicol. 2015;117:297-305. doi: 10.1111/bcpt.12407.
20. Pflug BR, Zheng H, Udan MS, D’Antonio JM, Marshall FF, Brooks JD, et al. Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett. 2007;246:139-148. doi: 10.1016/j.canlet.2006.02.007.
21. Absi M, Ward DT. Increased endothelin-1 responsiveness in human coronary artery smooth muscle cells exposed to 1,25-dihydroxyvitamin D(3). Am J Physiol Cell Physiol. 2013;304:C666-C672. doi: 10.1152/ajpcell.00349.2012.
22. El Safoury OS, Ezzat M, Abdelhamid MF, Shoukry N, Badawy E. The Evaluation of the Impact of Age, Skin Tags, Metabolic Syndrome, Body Mass Index, and Smoking on Homocysteine, Endothelin-1, High-sensitive C-reactive Protein, and on the Heart. Indian J Dermatol. 2013;58:326. doi: 10.4103/0019-5154.113947.
23. Zhu HJ, Lu S, Su W, Gong SY, Zhang ZB, Li P, et al. Effects of liandou qingmai recipe (see text) on endothelin-1, nitric oxide, interleukin-6 and interleukin-10 levels in patients with coronary heart disease. J Tradit Chin Med. 2011;31:173-177.
24. Ding SK, Wang LX, Guo LS. [Effect of percutaneous coronary intervention on coronary microcirculation instable angina patients. J Med Forum. 2016;37:81-82.